Underberg Sharon E. 4

What Happened

• Sharon E. Underberg, EVP, General Counsel & Corporate Secretary of IDEXX Laboratories (IDXX), received equity awards on Feb 12, 2026 (derivative awards) and converted/exercised a set of derivative awards on Feb 14, 2026. Several conversions were recorded (173, 176, 218 and 265 shares) and 251 shares were surrendered/ disposed to cover tax withholding at $629.35 per share, totaling $157,967. The Feb 12 entries show grants of derivative awards (RSUs/options) totaling 4,791 units (3,738 + 162 + 891).

Key Details

• Dates: Grants on Feb 12, 2026; conversions/exercises and withholding on Feb 14, 2026; Form 4 filed Feb 17, 2026.
• Withholding/tax sale: 251 shares withheld/disposed at $629.35 per share (closing price per footnote) = $157,967.
• Award/derivative activity: Conversions/exercises of 173, 176, 218 and 265 derivative units were recorded (these show $0 exercise price, consistent with RSU vesting/conversion rather than an option purchase).
• Grants: Feb 12 grants (derivative) total 4,791 units. Footnotes indicate the company used a mix of stock options (vesting schedules in 2027–2030) and restricted stock units (RSUs) vesting over multiple years.
• ESPP holdings: Footnote shows 333.654 shares held in the Issuer Employee Stock Purchase Plan (including 21 shares purchased in 2025).
• Filing: Form 4 filed Feb 17, 2026 for Feb 12–14 activity — appears to be a standard, timely filing.

Context

• This filing primarily reflects compensation-related equity activity (awards/RSU conversions) and a routine tax-withholding disposition (often called a “sell to cover”); it is not an open-market investment decision. When derivative entries show $0 exercise price, that typically indicates RSUs converting into common shares rather than paying cash to exercise an option.